1H2021 results

Analysts mixed on Raffles Medical even as it appears immunised to the Covid-19 bug - THE EDGE SINGAPORE

Broker's Calls

Analysts mixed on Raffles Medical even as it appears immunised to the Covid-19 bug

The group’s PATMI of $39.4 million beat expectations of analysts from RHB and CGS-CIMB.
Vicplas International reports 2.2 times earnings growth for 1HFY21 - THE EDGE SINGAPORE

Results

Vicplas International reports 2.2 times earnings growth for 1HFY21

Revenue from its medical segment grew 36% on increased customer orders.
iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21 - THE EDGE SINGAPORE

Broker's Calls

iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21

PhillipCapital is maintaining its “buy” call on iX Biopharma, but at a lower target price of 44.5 cents.
Oxley reports 117% surge in 1H21 earnings of $34.1 mil on higher revenue, lower finance costs - THE EDGE SINGAPORE

Results

Oxley reports 117% surge in 1H21 earnings of $34.1 mil on higher revenue, lower finance costs

Earnings per share (EPS) for the period stood at 0.81 cents compared to 0.37 cents the year before.
Thomson Medical Group reports profit of $9.7 mil for 1H21 reversing from losses the year before - THE EDGE SINGAPORE

Results

Thomson Medical Group reports profit of $9.7 mil for 1H21 reversing from losses the year before

Excluding Covid-19 related grants, the group recorded a net profit after tax (NPAT) of $4.5 million.
  •  
×